InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.030 -0.024 (-44.44%)+
Announcement
Release
27 Mar 2026 8:55AM
Price at Release
$0.054
Full Release
download
Summary
Firebrick Pharma Limited has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, marking a pivotal milestone for the company. The approval permits the importation and marketing of Nasodine as an 'antiseptic' product under the 'Household Health Supplies' category. With this approval, Firebrick can begin importation and distribution, contingent upon local requirements including language-specific packaging and securing a marketing partner. The Product Registration Services Agreement with PT Pyridam Farma Tbk outlines the operational framework, lasting until June 2030 with options for renewal. This strategic move into the Indonesian market, valued as Southeast Asia's largest, represents a significant growth opportunity for Firebrick.
Key Points
  • Nasodine Nasal Spray approved for importation in Indonesia
  • First regulatory approval for Nasodine
  • Agreement with PT Pyridam Farma Tbk
  • Term of agreement until June 2030
  • Importance of securing local marketing partner
  • Manufacturing in local language packaging required
  • Pivotal event for Firebrick in Southeast Asia’s largest market
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.